Wietske Woliner-Van der Weg

Wietske Woliner-Van der Weg

Auto-generated profile, based on publicly available information

Wietske Woliner-Van der Weg

Department of Dermatology Radboud University Medical Centre Nijmegen the Netherlands

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 July 2020 in British Journal of Dermatology
Verified
Journal Article
Open access
PDF file
WWW. Woliner–Van der Weg
W. Woliner–Van der Weg
MPM. Peppelman
M. Peppelman
YEY.S. Elshot
Y.S. Elshot
MVM.B. Visch
M.B. Visch
MCM.B. Crijns
M.B. Crijns
SLS.F.K. Lubeek
S.F.K. Lubeek
Background Reflectance confocal microscopy (RCM) is a non‐invasive method for skin assessment, allowing entire lesion evaluation up to the papillary dermis. Therefore, RCM is a potentially attractive alternative to punch biopsy in basal cell carcinoma (BCC). Objectives and design This randomized controlled trial aimed to investigate RCM as alternative to punch biopsy in a real‐world clinical setting. Primary objective was to determine the diagnostic accuracy of RCM compared to punch biopsy in diagnosing and subtyping BCC. Secondary objectives were to study related patient satisfaction and preferences. Methods Patients with a clinically suspected primary BCC were randomized between RCM and biopsy. Conventional surgical excision or follow‐up were used as reference. Sensitivity and specificity for BCC diagnosis and subtyping were calculated for both methods. BCC subtype was stratified based on clinical relevance: aggressive (infiltrative/micronodular) versus non‐aggressive (superficial/nodular) histopathological subtype and superficial versus non‐superficial BCC. Data on patient satisfaction and preferences werecollected using a questionnaire and a contingent valuation method. Results Sensitivity for BCC diagnosis was high and similar for both methods (RCM 99.0% versus biopsy 99.0%, p=1.00). Specificity for BCC diagnosis was lower with RCM (59.1% versus 100.0%, p<0.001). Sensitivity for aggressive BCC subtypeswas lower for RCM (33.3% versus 77.3%, p=0.003). Sensitivity for non‐superficial BCC was not significantly different (RCM 88.9% versus biopsy 91.0%, p=0.724). Patient satisfaction and preferences were good and highly comparable for both methods. Conclusions Biopsy outperforms RCM in diagnosing and subtyping clinically suspected primary BCC. This outcome does not support routine clinical implementation of RCM, as a replacement of punch biopsies in this patient group.

15 March 2019 in Cosmetics
Verified
Journal Article
Open access
PDF file
JLJade Logger
Jade Logger
JOJill Olydam
Jill Olydam
WWWietske Woliner-Van der Weg
Wietske Woliner-Van der Weg
Piet van ErpPiet van Erp
Piet van Erp
The epidermal barrier function is disrupted in various inflammatory skin diseases. Accurate methods to measure skin barrier function are needed to assess the effect of therapeutic agents. Therefore, we developed a noninvasive multiparametric approach to measure four different parameters regarding the skin barrier. In the current pilot study, we evaluate this method in 14 healthy volunteers. We assessed erythema, transepidermal water loss (TEWL), water content, and epidermal thickness at both cheeks before and 30 min after application of Lanette and Vaseline-Lanette cream. For this, we used spectrophotometry, the Aquaflux device, the Epsilon device, and reflection confocal microscopy, respectively. Stratum corneum (SC) thickness was significantly increased after application of both creams (p < 0.05), and this increase was larger after Lanette cream compared to after Vaseline-Lanette cream (p = 0.035). Erythema, TEWL, and water content did not significantly change after cream application. Our multiparametric approach is promising and offers a feasible and practical way to quickly obtain multifaceted information about skin barrier function. Further exploration of this approach after prolonged use of cream and in conditions of disrupted skin barrier are recommended areas for future research.

24 February 2015 in EJNMMI Physics
Verified
Journal Article
Open access
PDF file
WWWietske Woliner-Van der Weg
Wietske Woliner-Van der Weg
RSRafke Schoffelen
Rafke Schoffelen
RHRobert F Hobbs
Robert F Hobbs
Martin GotthardtMartin Gotthardt
Martin Gotthardt
DGDavid M Goldenberg
David M Goldenberg
EVEric P Visser
Eric P Visser
Red bone marrow (RBM) toxicity is dose-limiting in (pretargeted) radioimmunotherapy (RIT). Previous blood-based and two-dimensional (2D) image-based methods have failed to show a clear dose-response relationship. We developed a three-dimensional (3D) image-based RBM dosimetry approach using the Monte Carlo-based 3D radiobiological dosimetry (3D-RD) software and determined its additional value for predicting RBM toxicity. RBM doses were calculated for 13 colorectal cancer patients after pretargeted RIT with the two-step administration of an anti-CEA × anti-HSG bispecific monoclonal antibody and a 177Lu-labeled di-HSG-peptide. 3D-RD RBM dosimetry was based on the lumbar vertebrae, delineated on single photon emission computed tomography (SPECT) scans acquired directly, 3, 24, and 72 h after 177Lu administration. RBM doses were correlated to hematologic effects, according to NCI-CTC v3 and compared with conventional 2D cranium-based and blood-based dosimetry results. Tumor doses were calculated with 3D-RD, which has not been possible with 2D dosimetry. Tumor-to-RBM dose ratios were calculated and compared for 177Lu-based pretargeted RIT and simulated pretargeted RIT with 90Y. 3D-RD RBM doses of all seven patients who developed thrombocytopenia were higher (range 0.43 to 0.97 Gy) than that of the six patients without thrombocytopenia (range 0.12 to 0.39 Gy), except in one patient (0.47 Gy) without thrombocytopenia but with grade 2 leucopenia. Blood and 2D image-based RBM doses for patients with grade 1 to 2 thrombocytopenia were in the same range as in patients without thrombocytopenia (0.14 to 0.29 and 0.11 to 0.26 Gy, respectively). Blood-based RBM doses for two grade 3 to 4 patients were higher (0.66 and 0.51 Gy, respectively) than the others, and the cranium-based dose of only the grade 4 patient was higher (0.34 Gy). Tumor-to-RBM dose ratios would increase by 25% on average when treating with 90Y instead of 177Lu. 3D dosimetry identifies patients at risk of developing any grade of RBM toxicity more accurately than blood- or 2D image-based methods. It has the added value to enable calculation of tumor-to-RBM dose ratios.